Use of the Drospirenone-Only Contraceptive Pill in Adolescents with Endometriosis

Shim JY, Jessica Y. Shim, Garrett Garbo, Garrett Garborcauskas, Frances W Grimstad, Frances Grimstad, Grimstad FW, Scatoni A, Ava Scatoni, Ellis P Barrera, Ellis Barrera, Barrera EP, Elizabeth R. Boskey
Journal of Pediatric and Adolescent Gynecology · 2024 · vol. 37(4) , pp. 402–406 · doi:10.1016/j.jpag.2024.02.003 · PMID:38395193 · W4392005712
Observational OA: closed CC0 ⤵ 6 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-13 ⓘ

This retrospective cohort study found that the drospirenone-only pill effectively reduced pain and absence of bleeding/spotting in adolescents with endometriosis, with most tolerating the treatment.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

STUDY OBJECTIVE: To evaluate the efficacy and tolerability of a progestin-only pill containing 4 mg drospirenone (DRSP) as a hormonal therapy for the management of endometriosis-associated symptoms in adolescents and young adults. DESIGN: Retrospective cohort study. METHODS: A retrospective chart review was performed of all adolescents who were prescribed DRSP continuously (without placebo) for treatment of endometriosis at a single pediatric tertiary care center between 2019 and 2022. Electronic medical records were reviewed to obtain demographics and clinical characteristics of the patients. Measured outcomes included symptom resolution and medication discontinuation. The study was deemed IRB exempt. RESULTS: A total of 61 patients with endometriosis were prescribed DRSP during the study period, with a median age of 18.9 years (SD 2.3). The majority (97%) were laparoscopically confirmed to have endometriosis, and 85% had stage I disease. Before DRSP use, the most common medications trialed were norethindrone (57%) and norethindrone acetate (68%), and 56% had at least one medical contraindication to receiving estrogen-containing therapy. Of those with follow-up, 52% established an absence of bleeding/spotting, and 67% reported less pain at follow-up. One in 4 patients discontinued DRSP during the study period, most commonly due to breakthrough bleeding. CONCLUSION: DRSP is a well-tolerated and effective option for the treatment of endometriosis-associated symptoms in adolescents and young adults.

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Androstenes Androstenes Androstenes Androstenes Androstenes Androstenes Androstenes Androstenes Androstenes Androstenes Androstenes Androstenes Androstenes Androstenes Androstenes Androstenes Androstenes Androstenes Androstenes Androstenes

Citation neighborhood (2-hop)

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]

References (28)

Cited by (7)

Source provenance

europepmc
last seen: 2026-10-17T06:09:56.316927+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-10-17T06:07:55.739470+00:00
unpaywall
last seen: 2026-10-17T06:24:38.187582+00:00
License: CC0 · commercial use OK